Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASGR1 | P07306 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27029139 | 0.79 | — | — | |
| SCHEMBL18196979 | 0.71 | ASGR1 (0.38) | ASGR1CTSDCTSLCTSBCTSS | |
| SCHEMBL24204261 | 0.69 | CHRM2 (0.37) | ASGR1 | |
| SCHEMBL27029323 | 0.69 | ASGR1 (0.33) | ASGR1CTSDCTSLCTSBCTSS | |
| SCHEMBL23906171 | 0.67 | ASGR1 (0.35) | ASGR1 | |
| SCHEMBL24937070 | 0.67 | USP2 (0.36) | ASGR1CTSDCTSLCTSBCTSS | |
| SCHEMBL224478 | 0.67 | HSD11B1 (0.42) | ASGR1CTSDCTSLCTSBCTSS | |
| SCHEMBL24937071 | 0.67 | USP2 (0.36) | ASGR1CTSDCTSLCTSBCTSS | |
| SCHEMBL25075599 | 0.67 | HDAC6 (0.33) | ASGR1CTSDCTSLCTSBCTSS | |
| SCHEMBL24937073 | 0.67 | ASGR1 (0.36) | ASGR1CTSDCTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4574214-A2 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | Schrödinger, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| EP-4308573-B1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHROEDINGER INC (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20240199634-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. | 2024-06-20 | — | — | US | disclosed |
| EP-4308573-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | Schrödinger, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-117120447-A | Cyclic compounds and methods of use thereof | 薛定谔公司 | 2023-11-24 | — | — | CN | disclosed |
| WO-2022197898-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199634-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | PLK1, DCK, CSNK1A1 | ASGR1 2411/4885CTSD 2316/4885CTSL 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.